title: Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators.
abstract: Insulin resistance is characteristic of many patients with polycystic ovary syndrome (PCOS). Several studies have suggested that a decrease in insulin receptor (IR) autophosphorylation is a significant component of this resistance. In this study, we have used a highly sensitive ELISA to measure IR tyrosine phosphorylation in fibroblasts from patients with PCOS and healthy control women. After the stimulation of intact fibroblasts with insulin, IR tyrosine phosphorylation in cells from the PCOS patients was decreased by approximately 40% when compared with controls. However, when IR were first immunocaptured from fibroblasts and then stimulated with insulin, neither basal nor insulin-stimulated IR autophosphorylation was different between the two groups, suggesting that a factor independent of the IR was involved. To examine the role of increased serine kinase activity in decreased IR autophosphorylation in PCOS, fibroblasts from PCOS patients were pretreated with inhibitors of serine kinases before insulin stimulation. Pretreatment with H7, a nonspecific protein kinase inhibitor, completely reversed the decrease in insulin-stimulated IR autophosphorylation. Pretreatment with H89, an inhibitor of protein kinase A, partially reversed this function, whereas pretreatment with Gö6983, an inhibitor of protein kinase C, was without effect. We next studied the effects of two small molecule activators of the IR tyrosine kinase: TLK16998 and Merck L7. Both TLK16998 and Merck L7 were able to reverse the impaired insulin-stimulated IR autophosphorylation. In summary, a factor(s) extrinsic to the IR cause impaired IR signaling in fibroblasts from patients with PCOS. Reversal of the impaired IR signaling by inhibitors of serine kinase activity suggests that serine kinase-mediated pathways may be involved in the insulin resistance. Moreover, the observation that TLK16998 and Merck L7 improved IR tyrosine phosphorylation in fibroblasts from patients with PCOS suggests that specific pharmacological therapies might be developed to treat the insulin resistance in PCOS.
authors.affiliation: University of California at San Francisco, Mount Zion Medical Center, San Francisco, California 94143, USA.
authors.forename: Ming
authors.initials: M
authors.lastname: Li
authors.forename: Jack F
authors.initials: JF
authors.lastname: Youngren
authors.forename: Andrea
authors.initials: A
authors.lastname: Dunaif
authors.forename: Ira D
authors.initials: ID
authors.lastname: Goldfine
authors.forename: Betty A
authors.initials: BA
authors.lastname: Maddux
authors.forename: Bei B
authors.initials: BB
authors.lastname: Zhang
authors.forename: Joseph L
authors.initials: JL
authors.lastname: Evans
mesh_terms: D000293:Adolescent; D000328:Adult; D001391:Azo Compounds / Q000494:pharmacology*; D002460:Cell Line; D002478:Cells, Cultured; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005260:Female; D005347:Fibroblasts / Q000378:metabolism*; D006801:Humans; D007333:Insulin Resistance / Q000502:physiology*; D007700:Kinetics; D009281:Naphthalenes / Q000494:pharmacology*; D010766:Phosphorylation; D011085:Polycystic Ovary Syndrome / Q000378:metabolism*; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors*; D011972:Receptor, Insulin / Q000187:drug effects / Q000378:metabolism*; D012016:Reference Values
chemical_list: D001391:Azo Compounds; D004791:Enzyme Inhibitors; D009281:Naphthalenes; C423845:TLK 16998; D011972:Receptor, Insulin; D017346:Protein Serine-Threonine Kinases